Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection
نویسندگان
چکیده
Vimalanand S. Prabhu, Oliver A. Cornely, Yoav Golan, Erik R. Dubberke, Sebastian M. Heimann, Mary E. Hanson, Jane Liao, Alison Pedley, Mary Beth Dorr, and Stephen Marcella Economic and Data Sciences, Center for Real World and Observational Studies, Merck & Co., Inc., Kenilworth, New Jersey; Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, Department of Internal Medicine, Clinical Trials Centre Cologne, University of Cologne, Germany; Department of Medicine, Geographic Medicine and Infectious Diseases, Tufts University School of Medicine, Boston, Massachusetts; Division of Infectious Diseases, Washington University School of Medicine, St Louis, Missouri; Department of Internal Medicine, University Hospital of Cologne, Germany, Global Scientific and Medical Publications, Infectious Diseases & Vaccines, Statistical Programming for Center for Outcomes Research Excellence, Biostatistics, Late Development Statistics, Clinical Research, Infectious Diseases, and Outcomes Research, Center for Outcomes Research Excellence, Acute Hospital & Specialty Care, Merck & Co., Inc., Kenilworth, New Jersey
منابع مشابه
Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection
Clostridium difficile infection (CDI) is the most common health care-acquired infection associated with high hospital expenditures. The incidence of subsequent recurrent CDI increases with prior episodes of CDI, 15%-35% risk after primary CDI to 35%-65% risk after the first recurrent episode. Recurrent CDI is one of the most challenging and a very difficult to treat infections. Standard guideli...
متن کاملAntibiotics for Treatment of Clostridium difficile Infection in Hospitalized Patients with Inflammatory Bowel Disease.
Patients with inflammatory bowel disease (IBD), namely ulcerative colitis (UC) and Crohn's disease (CD), have worse outcomes with Clostridium difficile infection (CDI), including increased readmissions, colectomy, and death. Oral vancomycin is recommended for the treatment of severe CDI, while metronidazole is the standard of care for nonsevere infection. We aimed to assess treatment outcomes o...
متن کاملDetection of Virulence Genes of Clostridium difficile in Children with Cancer by Multiplex PCR
Introduction: Toxigenic Clostridium difficile is the major cause of antibiotic-associated diarrhea, colitis, and pseudomembranous colitis. The pathogenicity of C. difficile is related to toxins A&B. Children with cancer are at risk of developing C. difficile infection (CDI) due to increased exposure to antibiotics, immunosuppression, and longer hospital stays. Recently, due to higher sensitivity...
متن کاملBezlotoxumab (BEZ) for Prevention of Clostridium Difficile Infection (CDI) Recurrence (rCDI): Outcomes in Patients with Substantial Renal Impairment (SRI)
متن کامل
Burden of Clostridium difficile infection on hospital readmissions and its potential impact under the Hospital Readmission Reduction Program.
BACKGROUND Both Clostridium [corrected] difficile infection (CDI) rates in hospitals and interest in reducing 30-day readmission rates have increased dramatically in the United States. The objective of this study was to characterize the burden of CDI on 30-day hospital readmissions at a tertiary care health-system. METHODS A patient discharge database was used to identify patients with a CDI ...
متن کامل